Tags

Type your tag names separated by a space and hit enter

Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.
EBioMedicine. 2021 Aug; 70:103495.E

Abstract

BACKGROUND

Children are underrepresented in the COVID-19 pandemic and often experience milder disease than adolescents and adults. Reduced severity is possibly due to recent and more frequent seasonal human coronaviruses (HCoV) infections. We assessed the seroprevalence of SARS-CoV-2 and seasonal HCoV specific antibodies in a large cohort in north-eastern France.

METHODS

In this cross-sectional seroprevalence study, serum samples were collected from children and adults requiring hospital admission for non-COVID-19 between February and August 2020. Antibody responses to SARS-CoV-2 and seasonal HCoV (229E, HKU1, NL63, OC43) were assessed using a bead-based multiplex assay, Luciferase-Linked ImmunoSorbent Assay, and a pseudotype neutralisation assay.

FINDINGS

In 2,408 individuals, seroprevalence of SARS-CoV-2-specific antibodies was 7-8% with three different immunoassays. Antibody levels to seasonal HCoV increased substantially up to the age of 10. Antibody responses in SARS-CoV-2 seropositive individuals were lowest in adults 18-30 years. In SARS-CoV-2 seronegative individuals, we observed cross-reactivity between antibodies to the four HCoV and SARS-CoV-2 Spike. In contrast to other antibodies to SARS-CoV-2, specific antibodies to sub-unit 2 of Spike (S2) in seronegative samples were highest in children. Upon infection with SARS-CoV-2, antibody levels to Spike of betacoronavirus OC43 increased across the whole age spectrum. No SARS-CoV-2 seropositive individuals with low levels of antibodies to seasonal HCoV were observed.

INTERPRETATION

Our findings underline significant cross-reactivity between antibodies to SARS-CoV-2 and seasonal HCoV, but provide no significant evidence for cross-protective immunity to SARS-CoV-2 infection due to a recent seasonal HCoV infection. In particular, across all age groups we did not observe SARS-CoV-2 infected individuals with low levels of antibodies to seasonal HCoV.

FUNDING

This work was supported by the « URGENCE COVID-19 » fundraising campaign of Institut Pasteur, by the French Government's Investissement d'Avenir program, Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases (Grant No. ANR-10-LABX-62-IBEID), and by the REACTing (Research & Action Emerging Infectious Diseases), and by the RECOVER project funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No. 101003589, and by a grant from LabEx IBEID (ANR-10-LABX-62-IBEID).

Authors+Show Affiliations

Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France; Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France. Electronic address: tom.woudenberg@pasteur.fr.Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France; Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France.Molecular Virology and Vaccinoloy Unit, Department of Virology, Institut Pasteur, Paris, France.Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France; Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France.Laboratoire de Microbiologie, Groupement Hospitalier Régional de Mulhouse et Sud-Alsace, Mulhouse, France.Laboratoire de Microbiologie, Groupement Hospitalier Régional de Mulhouse et Sud-Alsace, Mulhouse, France.Centre Hospitalier Simone Veil de Beauvais, Beauvais, France.Centre Hospitalier Simone Veil de Beauvais, Beauvais, France.CHR Metz Thionville, Metz, France.Service de Bactériologie-Virologie, Hôpital Bretonneau, CHRU de Tours, Tours, France.Service de Bactériologie-Virologie, Hôpital Bretonneau, CHRU de Tours, Tours, France.Service de Virologie, CHU Amiens Picardie, UR 4294 AGIR UPJV, Amiens, France.Service de Virologie, CHU Amiens Picardie, UR 4294 AGIR UPJV, Amiens, France.Service de Microbiologie, Hôpitaux Civils de Colmar, Colmar, France.Laboratoire de Virologie, CHU de Strasbourg, Strasbourg, France.Univ. Lille, CHU Lille, Urgences pédiatriques et maladies infectieuses, Lille, France.Univ. Lille, CHU Lille, Urgences pédiatriques et maladies infectieuses, Lille, France.Urgences Pédiatrique et Pédiatrie Générale Hopital Mère Enfant CHU de Nantes, Nantes, France.Service de Virologie CHU Nantes, Nantes, France.Service de Virologie CHU Nantes, Nantes, France.CHU Nantes, CIC FEA1413, INSERM, Nantes, France.Hôpital d'Enfants, CHRU de Nancy, Vandoeuvre-Les-Nancy, France; EA 3450, DevAH, Université de Lorraine, Vandoeuvre Lès Nancy, France.Pediatric Emergency Unit, Hôpital d'enfants, CHRU Nancy.CRBL, CHRU Nancy, Nancy, France.Urgences pédiatriques et pédiatrie générale, hôpitaux pédiatriques CHU Lenval, Nice.Urgences pédiatriques et pédiatrie générale, hôpitaux pédiatriques CHU Lenval, Nice.Pediatric Emergency Department, Hospital University of St Etienne, France.Pediatric Emergency Department, Hospital University of St Etienne, France.Urgences pédiatriques Hopital Clocheville, CHRU de Tours, Tours, France.Agence régionale de santé Hauts-de-France.Investigation Clinique et Accès aux Ressources Biologiques (ICAReB), Center for Translational Research, Institut Pasteur, Paris, France.Molecular Virology and Vaccinoloy Unit, Department of Virology, Institut Pasteur, Paris, France.Direction de la recherche médicale, Institut Pasteur, Paris, France.Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Paris, France; PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France. Electronic address: arnaud.fontanet@pasteur.fr.Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France; Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France. Electronic address: michael.white@pasteur.fr.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34304047

Citation

Woudenberg, Tom, et al. "Humoral Immunity to SARS-CoV-2 and Seasonal Coronaviruses in Children and Adults in North-eastern France." EBioMedicine, vol. 70, 2021, p. 103495.
Woudenberg T, Pelleau S, Anna F, et al. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France. EBioMedicine. 2021;70:103495.
Woudenberg, T., Pelleau, S., Anna, F., Attia, M., Donnadieu, F., Gravet, A., Lohmann, C., Seraphin, H., Guiheneuf, R., Delamare, C., Stefic, K., Marlet, J., Brochot, E., Castelain, S., Augereau, O., Sibilia, J., Dubos, F., Meddour, D., Guen, C. G., ... White, M. (2021). Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France. EBioMedicine, 70, 103495. https://doi.org/10.1016/j.ebiom.2021.103495
Woudenberg T, et al. Humoral Immunity to SARS-CoV-2 and Seasonal Coronaviruses in Children and Adults in North-eastern France. EBioMedicine. 2021;70:103495. PubMed PMID: 34304047.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France. AU - Woudenberg,Tom, AU - Pelleau,Stéphane, AU - Anna,François, AU - Attia,Mikael, AU - Donnadieu,Françoise, AU - Gravet,Alain, AU - Lohmann,Caroline, AU - Seraphin,Hélène, AU - Guiheneuf,Raphaël, AU - Delamare,Catherine, AU - Stefic,Karl, AU - Marlet,Julien, AU - Brochot,Etienne, AU - Castelain,Sandrine, AU - Augereau,Olivier, AU - Sibilia,Jean, AU - Dubos,François, AU - Meddour,Damia, AU - Guen,Christèle Gras-Le, AU - Coste-Burel,Marianne, AU - Imbert-Marcille,Berthe-Marie, AU - Chauvire-Drouard,Anne, AU - Schweitzer,Cyril, AU - Gatin,Amélie, AU - Lomazzi,Sandra, AU - Joulié,Aline, AU - Haas,Hervé, AU - Cantais,Aymeric, AU - Bertholon,Frederique, AU - Chinazzo-Vigouroux,Marie-France, AU - Abdallah,Mohamed Si, AU - Arowas,Laurence, AU - Charneau,Pierre, AU - Hoen,Bruno, AU - Demeret,Caroline, AU - Werf,Sylvie Van Der, AU - Fontanet,Arnaud, AU - White,Michael, Y1 - 2021/07/23/ PY - 2021/04/26/received PY - 2021/06/25/revised PY - 2021/07/05/accepted PY - 2021/7/26/pubmed PY - 2021/9/15/medline PY - 2021/7/25/entrez KW - COVID-19 KW - SARS-CoV-2 KW - antibody response KW - seasonal coronaviruses KW - sero-epidemiology KW - seroprevalence SP - 103495 EP - 103495 JF - EBioMedicine JO - EBioMedicine VL - 70 N2 - BACKGROUND: Children are underrepresented in the COVID-19 pandemic and often experience milder disease than adolescents and adults. Reduced severity is possibly due to recent and more frequent seasonal human coronaviruses (HCoV) infections. We assessed the seroprevalence of SARS-CoV-2 and seasonal HCoV specific antibodies in a large cohort in north-eastern France. METHODS: In this cross-sectional seroprevalence study, serum samples were collected from children and adults requiring hospital admission for non-COVID-19 between February and August 2020. Antibody responses to SARS-CoV-2 and seasonal HCoV (229E, HKU1, NL63, OC43) were assessed using a bead-based multiplex assay, Luciferase-Linked ImmunoSorbent Assay, and a pseudotype neutralisation assay. FINDINGS: In 2,408 individuals, seroprevalence of SARS-CoV-2-specific antibodies was 7-8% with three different immunoassays. Antibody levels to seasonal HCoV increased substantially up to the age of 10. Antibody responses in SARS-CoV-2 seropositive individuals were lowest in adults 18-30 years. In SARS-CoV-2 seronegative individuals, we observed cross-reactivity between antibodies to the four HCoV and SARS-CoV-2 Spike. In contrast to other antibodies to SARS-CoV-2, specific antibodies to sub-unit 2 of Spike (S2) in seronegative samples were highest in children. Upon infection with SARS-CoV-2, antibody levels to Spike of betacoronavirus OC43 increased across the whole age spectrum. No SARS-CoV-2 seropositive individuals with low levels of antibodies to seasonal HCoV were observed. INTERPRETATION: Our findings underline significant cross-reactivity between antibodies to SARS-CoV-2 and seasonal HCoV, but provide no significant evidence for cross-protective immunity to SARS-CoV-2 infection due to a recent seasonal HCoV infection. In particular, across all age groups we did not observe SARS-CoV-2 infected individuals with low levels of antibodies to seasonal HCoV. FUNDING: This work was supported by the « URGENCE COVID-19 » fundraising campaign of Institut Pasteur, by the French Government's Investissement d'Avenir program, Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases (Grant No. ANR-10-LABX-62-IBEID), and by the REACTing (Research & Action Emerging Infectious Diseases), and by the RECOVER project funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No. 101003589, and by a grant from LabEx IBEID (ANR-10-LABX-62-IBEID). SN - 2352-3964 UR - https://www.unboundmedicine.com/medline/citation/34304047/Humoral_immunity_to_SARS_CoV_2_and_seasonal_coronaviruses_in_children_and_adults_in_north_eastern_France_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2352-3964(21)00288-7 DB - PRIME DP - Unbound Medicine ER -